Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections

References

• ChamilosGLunaMLewisREInvasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003)Haematologica20069198698916757415
   PubMed Web of Science ®Google Scholar
• PappasPGAlexanderBDAndesDRInvasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)Clin Infect Dis2010501101111120218876
   PubMed Web of Science ®Google Scholar
• KontoyiannisDPMarrKAParkBJProspective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) DatabaseClin Infect Dis2010501091110020218877
   PubMed Web of Science ®Google Scholar
• PaganoLCairaMCandoniAInvasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry studyHaematologica20109564465019850903
   PubMed Web of Science ®Google Scholar
• Dodds-AshleyESLewisRELewisJSnMartinCAndesDPharmacology of systemic antifungal agentsClin Infect Dis200643S28S39
   Web of Science ®Google Scholar
• AndesDRSafdarNBaddleyJWImpact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trialsClin Infect Dis2012541110112222412055
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBHeepMSingle-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteersAntimicrob Agents Chemother20065027928516377698
   PubMed Web of Science ®Google Scholar
• MiceliMHKauffmanCAIsavuconazole: a new broad-spectrum triazole antifungal agentClin Infect Dis2015611558156526179012
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdWiederholdNPIsavuconazole: a comprehensive review of spectrum of activity of a new triazoleMycopathologia201017029131320524153
   PubMed Web of Science ®Google Scholar
• PfallerMARhombergPRMesserSAJonesRNCastanheiraMIsavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff valuesDiagn Microbiol Infect Dis20158230331325986029
   PubMed Web of Science ®Google Scholar
• Espinel-IngroffAChowdharyAGonzalezGMMulticenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution methodAntimicrob Agents Chemother20155966666825313209
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdWiederholdNPSuttonDAFothergillAPattersonTFIn vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia speciesJ Antimicrob Chemother200964798319406849
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdWiederholdNPFothergillAWVallorACWickesBLPattersonTFAntifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformansAntimicrob Agents Chemother20095330931118955539
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdFothergillAWWiederholdNPVallorACWickesBLPattersonTFEvaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformansAntimicrob Agents Chemother2008522959296118559645
   PubMed Web of Science ®Google Scholar
• DattaKRheePByrnesE3rdIsavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibilityJ Clin Microbiol2013513090309323804388
   PubMed Web of Science ®Google Scholar
• Espinel-IngroffAChowdharyAGonzalezGMMulticenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution methodAntimicrob Agents Chemother2013573823382823716059
   PubMed Web of Science ®Google Scholar
• van der LindenJWArendrupMCWarrisAProspective multicenter international surveillance of azole resistance in Aspergillus fumigatusEmerg Infect Dis2015211041104425988348
   PubMed Web of Science ®Google Scholar
• GregsonLGoodwinJJohnsonAIn vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazoleAntimicrob Agents Chemother2013575778578024041890
   PubMed Web of Science ®Google Scholar
• WarnPASharpADenningDWIn vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus sppJ Antimicrob Chemother20065713513816284102
   PubMed Web of Science ®Google Scholar
• ArendrupMCJensenRHMeletiadisJIn vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales orderAntimicrob Agents Chemother2015597735774226438494
   PubMed Web of Science ®Google Scholar
• LepakAJMarchilloKVanheckerJAndesDRIsavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatusAntimicrob Agents Chemother2013576284628924100500
   PubMed Web of Science ®Google Scholar
• BoxHLivermoreJJohnsonAPharmacodynamics of isavuconazole in a dynamic in vitro model of invasive pulmonary AspergillosisAntimicrob Agents Chemother20156027828726503648
   PubMed Web of Science ®Google Scholar
• SeyedmousaviSBruggemannRJMeisJFMelchersWJVerweijPEMoutonJWPharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelAntimicrob Agents Chemother2015592855286625753636
   PubMed Web of Science ®Google Scholar
• LepakAJMarchilloKVanHeckerJDiekemaDAndesDRIsavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis modelAntimicrob Agents Chemother2013575642564824002092
   PubMed Web of Science ®Google Scholar
• LuoGGebremariamTLeeHEdwardsJEJrKovandaLIbrahimASIsavuconazole therapy protects immunosuppressed mice from mucormycosisAntimicrob Agents Chemother2014582450245324492363
   PubMed Web of Science ®Google Scholar
• MajithiyaJSharpAParmarADenningDWWarnPAEfficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida kruseiJ Antimicrob Chemother20096316116619008255
   PubMed Web of Science ®Google Scholar
• NajvarLKWiederholdNPBocanegraROlivoMKirkpatrickWRPattersonTFIsavuconazole is effective for the treatment of experimental cryptococcal meningitisICAAC Poster M-4272014
   Google Scholar
• Schmitt-HoffmannAHRichterWFIsavuconazole is widely distributed in rat tissueEuropean Congress of Clinical Microbiology and Infectious Diseases (ECCMID)London, UKMarch 31–April 3, 2012P863
   Google Scholar
• WarnPASharpAParmarAMajithiyaJDenningDWHopeWWPharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effectAntimicrob Agents Chemother2009533453346119451288
   PubMed Web of Science ®Google Scholar
• FalciDRPasqualottoACProfile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsInfect Drug Resist2013616317424187505
   PubMedGoogle Scholar
• FDA Advisory Committee Briefing DocumentIsavuconazonium Invasive Aspergillosis and Invasive Mucormycosis2015 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM430748.pdfAccessed January 15, 2016
   Google Scholar
• Astellas Pharma USPrescribing information for Cresemba 20152015 Available from: www.astellas.us/docs/cresemba.pdfAccessed January 15, 2016
   Google Scholar
• Schmitt-HoffmannARoosBMaaresJMultiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteersAntimicrob Agents Chemother20065028629316377699
   PubMed Web of Science ®Google Scholar
• Ananda-RajahMRKontoyiannisDIsavuconazole: a new extended spectrum triazole for invasive mold diseasesFuture Microbiol20151069370826000646
   PubMed Web of Science ®Google Scholar
• GubbinsPOTriazole antifungal agents drug-drug interactions involving hepatic cytochrome P450Expert Opin Drug Metab Toxicol201171411142921995615
   PubMed Web of Science ®Google Scholar
• AlbengresELe LouetHTillementJPSystemic antifungal agents. Drug interactions of clinical significanceDrug Saf19981883979512916
   PubMed Web of Science ®Google Scholar
• BaciewiczAMChrismanCRFinchCKSelfTHUpdate on rifampin, rifabutin, and rifapentine drug interactionsCurr Med Res Opin20132911223136913
   PubMed Web of Science ®Google Scholar
• BatesDWYuDTClinical impact of drug-drug interactions with systemic azole antifungalsDrugs Today (Barc)20033980181314668935
   PubMed Web of Science ®Google Scholar
• BruggemannRJAlffenaarJWBlijlevensNMClinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agentsClin Infect Dis2009481441145819361301
   PubMed Web of Science ®Google Scholar
• ChanJDPharmacokinetic drug interactions of vinca alkaloids: summary of case reportsPharmacotherapy199818130413079855331
   PubMed Web of Science ®Google Scholar
• CraneJKShihHTSyncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadineAm J Med1993954454468213879
   PubMed Web of Science ®Google Scholar
• DannaouiESchwarzPLortholaryOIn vitro interactions between antifungals and immunosuppressive drugs against zygomycetesAntimicrob Agents Chemother2009533549355119451295
   PubMed Web of Science ®Google Scholar
• DepontFVargasFDutroncHDrug-drug interactions with systemic antifungals in clinical practicePharmacoepidemiol Drug Saf2007161227123317879355
   PubMed Web of Science ®Google Scholar
• EidenCPeyriereHTichitRInherited long QT syndrome revealed by antifungals drug-drug interactionJ Clin Pharm Ther20073232132417489884
   PubMed Web of Science ®Google Scholar
• FeldsteinACSmithDHPerrinNReducing warfarin medication interactions: an interrupted time series evaluationArch Intern Med20061661009101516682575
   PubMed Web of Science ®Google Scholar
• GubbinsPOMould-active azoles: pharmacokinetics, drug interactions in neutropenic patientsCurr Opin Infect Dis20072057958617975407
   PubMed Web of Science ®Google Scholar
• KramerMRAmitalAFuksLShitritDVoriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interactionClin Transplant201125E16316721158923
   PubMed Web of Science ®Google Scholar
• NarreddySManavathuEChandrasekarPHAlangadenGJRevankarSGIn vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetesJ Antimicrob Chemother20106570170320130026
   PubMed Web of Science ®Google Scholar
• NivoixYUbeaud-SequierGEngelPLevequeDHerbrechtRDrug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient careCurr Drug Metab20091039540919519346
   PubMed Web of Science ®Google Scholar
• SathiapalanRKEl-SolhHEnhanced vincristine neurotoxicity from drug interactions: case report and review of literaturePediatr Hematol Oncol20011854354611764105
   PubMed Web of Science ®Google Scholar
• SteinbachWJSchellWABlankenshipJROnyewuCHeitmanJPerfectJRIn vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatusAntimicrob Agents Chemother2004481664166915105118
   PubMed Web of Science ®Google Scholar
• PurkinsLWoodNKleinermansDNicholsDVoriconazole potentiates warfarin-induced prothrombin time prolongationBr J Clin Pharmacol200356Suppl 1242914616410
   PubMed Web of Science ®Google Scholar
• KimTJancelTKumarPFreemanAFDrug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoringJ Clin Pharm Ther Epub201586
   Web of Science ®Google Scholar
• AndesDPascualAMarchettiOAntifungal therapeutic drug monitoring: established and emerging indicationsAntimicrob Agents Chemother200953243418955533
   PubMed Web of Science ®Google Scholar
• WalshTJAnaissieEJDenningDWTreatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaClin Infect Dis20084632736018177225
   PubMed Web of Science ®Google Scholar
• CornelyOAArikan-AkdagliSDannaouiEESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013Clin Microbiol Infect201420Suppl 352624479848
   PubMed Web of Science ®Google Scholar
• MaertensJARaadIIMarrKAIsavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialLancet Epub2015129
   Web of Science ®Google Scholar
• MartyFMOstrosky-ZeichnerLCornelyOAIsavuconazole treatment for mucormycosis: open-label trial and contemporaneous case-control analysisLancet Infect Dis Epub2016
   Web of Science ®Google Scholar
• De PauwBWalshTJDonnellyJPRevised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClin Infect Dis2008461813182118462102
   PubMed Web of Science ®Google Scholar
• Oude LashofAMSobelJDRuhnkeMSafety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemiaAntimicrob Agents Chemother2012563133313722450974
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdLewisJS2ndPharmacology and clinical use of voriconazoleExpert Opin Drug Metab Toxicol20106839419947892
   PubMed Web of Science ®Google Scholar
• McLaughlinJMEquilsOSomervilleKTRisk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patientsTranspl Infect Dis20131532934323489832
   PubMed Web of Science ®Google Scholar
• ZwaldFOBrownMSkin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipientsJ Am Acad Dermatol201165253261 quiz 6221763561
   PubMed Web of Science ®Google Scholar
• ZwaldFOSprattMLemosBDDuration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantationDermatol Surg2012381369137422551390
   PubMed Web of Science ®Google Scholar
• WermersRACooperKRazonableRRFluoride excess and periostitis in transplant patients receiving long-term voriconazole therapyClin Infect Dis20115260461121239842
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdBaysDCohenSHPappagianisDFluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazolesAntimicrob Agents Chemother20125656356422005993
   PubMed Web of Science ®Google Scholar
• AllenKCSanchezCJJrNieceKLWenkeJCAkersKSVoriconazole enhances the osteogenic activity of human osteoblasts in vitro through a fluoride-independent mechanismAntimicrob Agents Chemother2015597205721326324277
   PubMed Web of Science ®Google Scholar
• GuineaJPelaezTRecioSTorres-NarbonaMBouzaEIn vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium speciesAntimicrob Agents Chemother2008521396140018212101
   PubMed Web of Science ®Google Scholar
• PerkhoferSLechnerVLass-FlorlCEuropean Committee on Anti microbial Susceptibility TestingIn vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the metho dology of the European Committee on Antimicrobial Susceptibility TestingAntimicrob Agents Chemother2009531645164719164153
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLINRodriguezJChenEPaetznickVComparative in vitro activity of isavuconazole (ISA) against medically important yeasts and mouldsPrograms and Abstracts of the 49th Annual ICAAC2009San Francisco Poster M-1707
   Google Scholar
• Curfs-BreukerIM D-OYEndtzHPVerweijPEMeisJFIn vitro activity of caspofungin compared with six other antifungal agents against 239 prospectively collected clinical Aspergillus isolates from the NetherlandsPrograms and Abstracts of the 3rd Advances Against Aspergillosis Annual Meeting2008Miami Poster 37
   Google Scholar
• Cuenca-EstrellaAGLABuitragoMJMelladoERodriguez-TudelaJLBAL4815 a new antifungal agent: Determination of quality control limits for susceptibility testing by methods of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)Programs and abstracts of the 46th Annual ICAAC Annual Meeting2006San Francisco Poster M-1571
   Google Scholar
• PelaezT GBGuineaJSanchez-CambroneroLAssessment of the antifungal susceptibility of Aspergillus terreus over an 18-year period in a general hospitalPrograms and abstracts of the 49th Annual ICAAC Annual Meeting2009San Francisco Poster M1714
   Google Scholar
• GuineaPTGamaBFloresRIs Aspergillus nidulans susceptible to all antifungal agents? In vitro activity of and updated panel of antifungal agents against 63 clinical isolatesPrograms and abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)Helsinki2009 Oral Presentation
   Google Scholar
• VerweijPEGonzalezGMWiedrholdNPIn vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countriesJ Chemother20092127228119567347
   PubMed Web of Science ®Google Scholar
• GonzalezGMIn vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungiMed Mycol200947717619101837
   PubMed Web of Science ®Google Scholar